

REMARKS

Applicants request entry of the substitute specification that accompanies these papers, pursuant to 37 C.F.R. §1.125(b). A marked-up copy and a clean copy of the substitute specification are included herewith.

Specifically, the substitute specification adds "SEQ ID NO" designations to amino acid and nucleotide sequences that appeared in the original specification as filed but did not include the required SEQ ID NO identifiers. No new matter is added to the substitute specification.

Also, a new sequence listing is submitted herewith. The original sequence listing included SEQ ID NOs: 1-50. In response to a Notification of Missing Requirements issued March 10, 2006 that included a Sequence Listing Error Report, a Replacement Sequence Listing was submitted on May 30, 2006. Upon a recent review of the specification, additional nucleotide and peptide sequences that were included in the original specification as filed but were not included in the submitted Sequence Listing were discovered. The replacement sequence listing submitted herewith includes these additional sequences designated SEQ ID NOs: 51-62, all of which appear in the original specification as filed.

Also, as outlined above, Applicants have included the priority data and Abstract for inclusion in the specification.

Applicants assert that no new matter is presented therein.

Entry of the foregoing amendments and allowance of the application are respectfully requested.

No fees are believed to be due with the submission of the enclosed documents; however, the Commissioner is authorized to charge any fees required in connection with the papers submitted herewith to Deposit Account No. 50-0268.

Respectfully submitted,

/David G. O'Brien/

Leon R. Yankwich, Reg. No. 30,237
David G. O'Brien, Reg. No. 46,125
Attorneys for Applicants

Certificate of Transmission via EFS WEB

The undersigned hereby certifies that this correspondence and accompanying documents are being electronically submitted to the U.S. Patent Office under 37 C.F.R. §1.8 on July 16, 2010.

/David G. O'Brien/

David G. O'Brien